IP Library › Patent Application 11194318
Patent Application
App. No. 11/194,318

Stabilized antihistamine syrup

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/194,318
Abstract

An antihistaminic syrup is stabilized against degradation of the active ingredient, by the addition of about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid, such as a salt of ethylenediaminetetraacetic acid.

Claims (23)

1 . An antihistaminic syrup formulation containing about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid, including salts thereof.

2 . The syrup of claim 1 , which contains an antihistaminic ingredient selected from the group consisting of: loratadine; descarboethoxyloratadine; azatadine; and any combination of two or more thereof.

3 . The syrup of claim 1 , which contains the antihistaminic ingredient loratadine.

4 . The syrup of claim 1 , which contains the antihistaminic ingredient descarboethoxyloratadine.

5 . The syrup of claim 1 , which contains the antihistaminic ingredient azatadine.

6 . The syrup of claim 1 , wherein the aminopolycarboxylic acid is selected from the group consisting of: iminodiacetic acid; methyliminodiacetic acid; nitrilotriacetic acid; ethylenediaminetetraacetic acid; diethylenetriaminepentaacetic acid; 1,2-diaminocyclohexane-tetraacetic acid; N-hydroxyethylenediaminetriacetic acid; and any combination of two or more thereof.

7 . The syrup of claim 1 , wherein the aminopolycarboxylic acid comprises ethylenediaminetetraacetic acid.

8 . The syrup of claim 1 , in which the aminopolycarboxylic acid comprises about 0.1 to 1 mg/mL.

9 . The syrup of claim 7 , in which the aminopolycarboxylic acid comprises about 0.25 to about 0.5 mg/mL.

10 . The syrup of claim 1 , further containing a therapeutically effective amount of a decongestant, an analgesic, an antitussive, an expectorant, or any combination of two or more thereof.

11 . The syrup of claim 1 , further containing a decongestant selected from the group consisting of pseudoephedrine and phenylpropanolamine.

12 . The syrup of claim 1 , further containing the decongestant pseudoephedrine.

13 . The syrup of claim 12 , which contains the antihistaminic ingredient loratadine.

14 . An antihistaminic syrup formulation containing loratadine or descarboethoxyloratadine and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid or a salt thereof.

15 . The syrup of claim 14 , wherein the aminopolycarboxylic acid is selected from the group consisting of: iminodiacetic acid; methyliminodiacetic acid; nitrilotriacetic acid; ethylenediaminetetraacetic acid; diethylenetriaminepentaacetic acid; 1,2-diaminocyclohexane-tetraacetic acid; N-hydroxyethylenediaminetriacetic acid; and any combination of two or more thereof.

16 . The syrup of claim 14 , wherein the aminopolycarboxylic acid comprises ethylenediaminetetraacetic acid.

17 . The syrup of claim 14 , in which the aminopolycarboxylic acid comprises about 0.1 to 1 mg/mL.

18 . The syrup of claim 14 , in which the aminopolycarboxylic acid comprises about 0.25 to about 0.5 mg/mL.

19 . The syrup of claim 14 , further containing an analgesic.

20 . The syrup of claim 14 , further containing a decongestant selected from the group consisting of pseudoephedrine and phenylpropanolamine.

21 . The syrup of claim 20 , further containing an analgesic.

22 . An antihistaminic syrup formulation containing loratadine and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid or a salt thereof.

23 . An antihistaminic syrup formulation containing descarboethoxyloratadine and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid or a salt thereof.